NDAORALTABLET
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
15
Data completeness
5/8 — Partial
XCOPRI (cenobamate) by SK Life Science is sodium channel antagonists [moa]. First approved in 2019.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XCOPRI (cenobamate) is an oral sodium channel antagonist approved by FDA in November 2019 for seizure management. It works by blocking sodium channels in the brain to reduce abnormal electrical activity. The drug is indicated for patients with epilepsy requiring additional seizure control.
$113MPart D
Peak12.7 years to LOEAt peak commercial performance with $113M in Part D spending, the product team is likely operating at full scale with established field and medical affairs infrastructure.
Mechanism of Action
Sodium Channel Antagonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain
Started Dec 2024
300 enrolled
Focal Epilepsy With and Without Secondary Generalization
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Started Oct 2024
49 enrolled
Focal Onset Seizure
Cenobamate in Adults With Focal-Onset Seizures
Started Jan 2023
936 enrolled
EpilepsyFocal-Onset SeizureNeurological Disorder
Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
Started Nov 2022
100 enrolled
Epilepsies, Partial
A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally
Started Sep 2022
24 enrolled
Healthy Volunteers
Worked on XCOPRI at SK Life Science? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.